Theralase Technologies (TLT) AI Stock Analysis

• Market Cap: C$50.13M
• Dividend Yield: N/A
• Average Volume (3M): 121.23K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.53
• Revenue Growth: 1.46%
• EPS Growth: 6.91%
• Country: CA
• Employees: 14
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 257,058,320
• 10 Day Avg. Volume: 149,922
• 30 Day Avg. Volume: 121,227
• PEG Ratio: 1.00
• Price to Book (P/B): 30.77
• Price to Sales (P/S): 61.56
• P/FCF Ratio: -19.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.20 ▲(11.67% Upside)

The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and significant equity depletion—despite modest leverage. Technicals are supportive (price above key moving averages with a positive MACD) but look overbought (high RSI/Stoch), and valuation is constrained by a negative P/E that reflects continued unprofitability.

Positive Factors

Proprietary PDT laser technology

Owning proprietary laser systems and PDT drug formulations establishes durable IP-based differentiation in a niche medical-device segment. This supports long-term product exclusivity, potential licensing revenue, and strategic partnerships with research hospitals, aiding sustainable competitive positioning.

Healthy gross margins on product sales

Near 50%+ gross margins on revenue indicate that when commercial traction improves, incremental sales can meaningfully contribute to profitability. Durable product-level margins support scalable profitability as fixed R&D and SG&A leverage with higher volumes over months to years.

Modest balance-sheet leverage

Relatively low debt-to-equity reduces near-term refinancing and interest burden risk, giving management flexibility to fund operations via equity or partnerships rather than onerous debt. This structural balance-sheet conservatism lowers bankruptcy risk while pursuing clinical and commercial milestones.

Negative Factors

Very small and declining revenue base

A ~$1M and shrinking revenue base signals limited commercial traction and market adoption. Over the next several months, sustaining operations and scaling product distribution will be difficult without meaningful top-line growth, hampering ability to reach durable breakeven and attract partners.

Extremely negative operating and net margins

Operating and net margins near -430% reflect structural unprofitability: losses vastly exceed sales, implying current cost base and investment profile are unsustainable without major revenue gains or expense restructuring, raising long-term dilution and execution risk.

Persistent cash burn and worsening FCF

Consistent negative operating and free cash flow, worsening year-over-year, creates ongoing funding needs. Over 2–6 months this increases dilution and partnership dependence risk, and it constrains sustained investment in commercialization or trials without new capital or strategic alliances.

Theralase Technologies Business Overview & Revenue Model

Company Description

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.

How the Company Makes Money

Theralase generates revenue primarily through the commercialization of its proprietary laser systems and photodynamic therapy products. This includes the sale of medical devices, treatment protocols, and related consumables to healthcare providers. Additionally, the company may earn revenue through licensing agreements, partnerships with pharmaceutical companies, and potential collaborations for clinical trials. The establishment of strategic partnerships with medical institutions and research organizations enhances its market reach and supports the development of its products, further contributing to its revenue streams.

Theralase Technologies Financial Statement Overview

Summary

Theralase Technologies faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. Despite low leverage, the reliance on external financing and negative profitability metrics indicate a need for strategic improvements.

Income Statement

Theralase Technologies has been experiencing declining revenue over the past few years, with a notable decrease from $1,138,569 in 2022 to $1,033,431 in 2024. The company has consistently reported negative net income, indicating ongoing losses. Gross profit margins have been low and deteriorating, reflecting challenges in cost management. The negative EBITDA and EBIT margins further highlight operational inefficiencies and lack of profitability.

Balance Sheet

The balance sheet shows a weakening position, with declining total assets and stockholders' equity over the years. The debt-to-equity ratio remains low due to minimal debt, which is a positive aspect. However, the equity ratio is declining, and the return on equity is negative due to continued losses, presenting a risk to financial stability.

Cash Flow

Theralase Technologies has been consistently generating negative operating cash flow and free cash flow, indicating struggles with generating cash from core operations. Free cash flow has shown some improvement in recent years but remains negative, highlighting cash management issues. Financing activities have been the primary source of cash, which could pose a risk if external funding becomes limited.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.00M	1.03M	1.07M	1.14M	780.64K	929.12K
Gross Profit	493.77K	554.03K	562.13K	628.17K	309.94K	269.68K
EBITDA	-4.07M	-3.96M	-4.25M	-4.90M	-4.31M	-5.56M
Net Income	-4.35M	-4.26M	-4.57M	-5.25M	-4.42M	-5.61M
Balance Sheet
Total Assets	3.00M	3.25M	3.28M	4.16M	5.94M	10.02M
Cash, Cash Equivalents and Short-Term Investments	80.99K	268.76K	43.91K	1.51M	3.69M	7.88M
Total Debt	319.72K	293.87K	386.88K	473.62K	35.72K	92.34K
Total Liabilities	1.91M	1.18M	1.37M	1.07M	874.79K	857.13K
Stockholders Equity	1.09M	2.07M	1.91M	3.09M	5.07M	9.16M
Cash Flow
Free Cash Flow	-2.61M	-3.35M	-4.11M	-5.20M	-4.13M	-4.61M
Operating Cash Flow	-2.52M	-3.33M	-4.07M	-5.13M	-4.03M	-4.45M
Investing Cash Flow	-97.89K	-19.97K	-37.27K	-70.41K	-100.82K	-164.58K
Financing Cash Flow	2.36M	3.57M	2.65M	3.02M	-57.37K	-57.56K

Theralase Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TLT, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.18, and below the 200-day MA of 0.19, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 73.65 is Negative, neither overbought nor oversold. The STOCH value of 82.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TLT.

Theralase Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
PRN	55 Neutral	C$427.52M	-6.31	-127.60%	―	72.03%	-1.47%
VPT	50 Neutral	C$20.96M	-5.04	―	―	28.59%	23.46%
TLT	46 Neutral	C$50.13M	-11.14	-269.41%	―	1.46%	6.91%
ASG	46 Neutral	C$21.07M	-11.16	-31.12%	―	9.71%	-118.02%
PINK	46 Neutral	C$31.91M	-1.43	-181.70%	―	209.29%	35.38%

Theralase Technologies Corporate Events

Theralase and Ferring Launch Combination Trial for BCG-Unresponsive Bladder Cancer

Ferring Pharmaceuticals and Theralase Technologies have signed a clinical development agreement to test a combination therapy using Ferring’s FDA-approved intravesical gene therapy ADSTILADRIN and Theralase’s investigational light-activated small molecule Ruvidar in patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in-situ, with or without papillary tumors. Theralase will remain the study sponsor under its ongoing Study II program, adding a new cohort in the United States that may expand to Canada or other countries, with both companies jointly overseeing development; the collaboration aims to enhance efficacy and durability of response by combining two complementary mechanisms of action and could strengthen Theralase’s clinical and regulatory trajectory for Ruvidar while reinforcing Ferring’s ambition to position ADSTILADRIN as a backbone therapy in this evolving treatment landscape.

The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.

Theralase Raises C$1.3 Million to Advance Bladder Cancer Trial

Theralase Technologies has closed a non-brokered private placement of 7,850,882 units at C$0.17 per unit, raising gross proceeds of approximately C$1.33 million. Each unit comprises one common share and one warrant exercisable at C$0.21 for five years, with the funds earmarked primarily to advance the company’s Phase II clinical study in non-muscle invasive bladder cancer, as well as for working capital and general corporate purposes. The financing, which includes finder fees paid in cash, shares and additional warrants, remains subject to final TSX Venture Exchange approval, and all securities issued will be subject to a standard Canadian hold period, underscoring both the company’s ongoing capital needs and its commitment to progress its cancer therapy pipeline.

The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.15 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.

Theralase Launches Private Placement to Fund Cancer Research

Theralase Technologies Inc. has initiated a non-brokered private placement to raise up to $CAN 2,000,000, with each unit priced at $CAN 0.17. The proceeds will support the ongoing Phase II clinical study for Non-Muscle Invasive Bladder Cancer and meet working capital needs. The company has also terminated a previously announced brokered financing agreement. This move is expected to bolster Theralase’s financial resources, aiding its research and development efforts in cancer treatment, and potentially strengthening its market position.

The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.15 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.

Theralase Technologies Secures Funding to Advance Cancer Treatment Study

Theralase Technologies Inc. has announced a brokered private placement offering to raise between C$4.5 million and C$5.5 million, with Research Capital Corporation as the sole agent. The funds will primarily support a Phase II clinical study for non-muscle invasive bladder cancer and other strategic initiatives, potentially enhancing Theralase’s market position in cancer treatment.

The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.

Theralase Reports Promising Cancer Study Results Amid Financial Challenges

Theralase Technologies Inc. has announced an investor conference call to update on its Phase II clinical study for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. The study shows promising interim results, with a 64.3% complete response rate among patients. Financially, the company reported a slight decrease in revenue and an increase in net loss for the nine months ended September 30, 2025. Despite these financial challenges, Theralase continues to pursue funding opportunities to support its clinical and commercial objectives.

The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.

Theralase Technologies Reports Q3 2025 Financials and Clinical Progress

Theralase Technologies Inc. has released its unaudited financial statements for the third quarter of 2025, reporting a 5% decrease in total revenue compared to the previous year. Despite a slight decrease in gross margin and an increase in net loss, the company continues to make progress in its clinical trials, with significant advancements in Study II. The company completed a private placement and extended warrant expiry dates to support its financial position, while also exploring additional funding opportunities. The ongoing clinical study has shown promising interim results, with a high percentage of patients achieving a complete or total response, indicating strong treatment durability.

The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.

Theralase’s Rutherrin® Shows Promise in Preclinical Cancer Treatment

Theralase Technologies announced promising preclinical results for their X-Ray-activated drug, Rutherrin®, which has shown significant effectiveness in treating various cancers. The drug, when activated by radiation therapy, demonstrated enhanced tumor destruction, overcoming treatment resistance, and stimulating systemic immunity. These findings position Rutherrin® as a potential breakthrough in cancer treatment, with plans for further toxicology studies and clinical development targeting several aggressive cancers.

The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.